Global sickle cell disease mortality burden was 376,000 in 2021; 81,100 deaths reported in children younger than 5 years<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, July 20, 2023 (HealthDay News) — Globally, sickle cell disease provides a high contribution to all-cause mortality, especially among children younger than 5 years, according to a study published online June 15 in The Lancet Haematology<\/em>.<\/p>\n Azalea M. Thomson, from the Institute for Health Metrics and Evaluation at the University of Washington in Seattle, and colleagues estimated cause-specific sickle cell disease mortality using standardized Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) approaches and estimated a more accurate account of sickle cell disease health burden using four types of epidemiological data across 204 countries and territories from 2000 to 2021.<\/p>\n The researchers found that the national incidence rates of sickle cell disease were relatively stable between 2000 and 2021, but there was a 13.7 percent global increase in total births of babies with sickle cell disease to 515,000, mainly due to population growth in the Caribbean and Western and Central sub-Saharan Africa. A 41.4 percent increase was seen in the number of people living with sickle cell disease globally, from 5.46 million in 2000 to 7.74 million in 2021. In 2021, 34,400 cause-specific all-age deaths were estimated globally, while the total sickle cell disease mortality burden was 376,000. There were 81,100 deaths in children younger than 5 years, ranking total sickle cell disease mortality as 12th across all causes estimated by the GBD in 2021 compared with 40th for cause-specific sickle cell disease mortality.<\/p>\n “In the U.S., newborn screening is universal, but a national registry does not yet exist,” a coauthor said in a statement. “Increased global awareness and adoption of health policies that expand neonatal screening and make treatment more accessible will go a long way in improving health outcomes.”<\/p>\n Several of the international group of GBD 2021 Sickle Cell Disease Collaborators disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n